185 related articles for article (PubMed ID: 28859739)
41. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.
Umezawa Y; Nakagawa H; Niiro H; Ootaki K;
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1957-1960. PubMed ID: 27358210
[TBL] [Abstract][Full Text] [Related]
42. New Injectable Drug Treats Moderate-To-Severe Plaque Psoriasis.
Aschenbrenner DS
Am J Nurs; 2017 Jun; 117(6):23. PubMed ID: 28541985
[No Abstract] [Full Text] [Related]
43. Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review.
Koo J; Ho RS; Thibodeaux Q
Cutis; 2019 Dec; 104(6):361-365. PubMed ID: 31939925
[TBL] [Abstract][Full Text] [Related]
44. Infliximab for the treatment of extensive plaque psoriasis--regulation, cost and reimbursement.
Rabinovich M; Fainaru M
Isr Med Assoc J; 2003 Nov; 5(11):817-8. PubMed ID: 14650110
[No Abstract] [Full Text] [Related]
45. Treatment of inverse psoriasis with efalizumab.
George D; Rosen T
J Drugs Dermatol; 2009 Jan; 8(1):74-6. PubMed ID: 19180901
[TBL] [Abstract][Full Text] [Related]
46. Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.
Cannavò SP; Postorino E; Aragona E; Bartolotta A; Papaianni V; Guarneri C
J Dermatolog Treat; 2018; 29(sup1):9-11. PubMed ID: 30247938
[TBL] [Abstract][Full Text] [Related]
47. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).
Chiricozzi A; Saraceno R; Novelli L; Fida M; Caso F; Scarpa R; Costa L; Perricone R; Romanelli M; Chimenti S; Chimenti MS
Expert Opin Ther Pat; 2016 Jul; 26(7):757-66. PubMed ID: 27266423
[TBL] [Abstract][Full Text] [Related]
48. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
Nijsten T; Spuls PI
Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
[No Abstract] [Full Text] [Related]
49. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
[TBL] [Abstract][Full Text] [Related]
50. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis.
Strober B; Zhao Y; Tran MH; Gnanasakthy A; Nyirady J; Papavassilis C; Nelson LM; McLeod LD; Mordin M; Gottlieb AB; Elewski BE; Lebwohl M
Int J Dermatol; 2016 Mar; 55(3):e147-55. PubMed ID: 26518255
[TBL] [Abstract][Full Text] [Related]
51. Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report.
Odorici G; Losi A; Ciardo S; Pellacani G; Conti A
Skin Res Technol; 2018 Feb; 24(1):160-162. PubMed ID: 29067742
[No Abstract] [Full Text] [Related]
52. Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.
Gisondi P; Bianchi L; Conti A; Dapavo P; Malagoli P; Piaserico S; Savoia F; Prignano F; Girolomoni G
Br J Dermatol; 2017 Dec; 177(6):e325-e326. PubMed ID: 28498543
[No Abstract] [Full Text] [Related]
53. Rebound pustular psoriasis after brodalumab discontinuation.
Khemis A; Cavalié M; Montaudié H; Lacour JP; Passeron T
Br J Dermatol; 2016 Nov; 175(5):1065-1066. PubMed ID: 27037661
[No Abstract] [Full Text] [Related]
54. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
[TBL] [Abstract][Full Text] [Related]
55. Brodalumab for the treatment of psoriasis.
Galluzzo M; D'adamio S; Bianchi L; Talamonti M
Expert Rev Clin Immunol; 2016 Dec; 12(12):1255-1271. PubMed ID: 27718760
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
[TBL] [Abstract][Full Text] [Related]
57. Crisaborole 2% Ointment (Eucrisa
Gupta AK; Versteeg SG; Abramovits W; Vincent KD
Skinmed; 2017; 15(5):377-380. PubMed ID: 29139367
[No Abstract] [Full Text] [Related]
58. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
59. New drugs in the treatment of psoriasis.
DiSepio D; Chandraratna RA
Expert Opin Investig Drugs; 2000 Jan; 9(1):79-93. PubMed ID: 11060662
[TBL] [Abstract][Full Text] [Related]
60. Guselkumab (Tremfya) for psoriasis.
Med Lett Drugs Ther; 2017 Nov; 59(1533):179-180. PubMed ID: 29125591
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
